M&A / Deals Pathos AI signs two cancer deals with Alphamab and AZ PharmaphorumPathos AI has grown its oncology pipeline by licensing a bispecific ADC from Alphamab for $125m and partnering a breast cancer drug from AstraZeneca.OncologyRead full story pharminent August 4, 2026 (Last updated: August 8, 2026) Pharmaphorum Pathos AI has grown its oncology pipeline by licensing a bispecific ADC from Alphamab for $125m and partnering a breast cancer drug from AstraZeneca. Oncology Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: AstraZeneca and Bristol Myers Squibb Reported to Have Held Mega-Merger TalksNext: Supernus and Indivior merge to create scaled, CNS-focused entity Related Stories M&A / Deals Mediar and Ono Pharmaceutical to develop fibro-inflammatory treatments pharminent August 7, 2026 M&A / Deals Supernus and Indivior merge to create scaled, CNS-focused entity pharminent August 4, 2026 M&A / Deals Supernus and Indivior merge to create CNS mega-company with 11 approved drugs pharminent August 3, 2026
